Johnson & Johnson ranks eighth on the 2025 Innovation Index and second on the Invention Index, with notable strides being made in oncology, immunology, cardiology, and rare diseases.

In oncology, results from the Phase 3 MARIPOSA study led to the European approval of Rybrevant (amivantamab) and Lazcluze (lazertinib) for the first-line treatment of advanced NSCLC with specific EGFR mutations—namely, exon 19 deletions or exon 21 (L858R) substitutions. Additionally, Carvykti (ciltacabtagene autoleucel) demonstrated significant improvements in progression-free and overall survival in relapsed or refractory multiple myeloma, establishing a new benchmark in cell therapy.

In immunology, Tremfya (guselkumab) expanded its indications, with new approvals for both ulcerative colitis and Crohn's disease, demonstrating superior clinical benefits in biologic-naïve and biologic-refractory patients. Simponi (golimumab) saw expanded use in pediatric ulcerative colitis.

Johnson & Johnson made significant progress in rare diseases, with Imaavy (nipocalimab) continuing to impress in Phase 2/3 trials for generalized myasthenia gravis and Sjögren’s disease. Nipocalimab also earned Breakthrough Therapy Designation from the FDA for the treatment of high-risk hemolytic disease of the fetus and newborn, marking a significant step forward in its potential use for rare autoimmune diseases.

Johnson & Johnson also formed key collaborations, such as with Kaken Pharmaceutical, to advance its STAT6 program for autoimmune and allergic diseases, including atopic dermatitis.

With a robust pipeline and continued innovations in both established and emerging fields, Johnson & Johnson remains a major player in advancing healthcare globally.